title: Enzyme replacement therapy with agalsidase alfa in a cohort of Italian patients with Anderson-Fabry disease: testing the effects with the Mainz Severity Score Index.
abstract: Anderson-Fabry disease (AFD) is a rare X-linked disorder caused by lysosomal storage of several glycosphingolipids, affecting virtually all organs and systems. Enzyme replacement therapy (ERT) for AFD has been available since 2001. Due to the highly variable nature of clinical manifestations in patients with AFD, it is very difficult to assess disease progression and the effects of therapy. We used the Mainz Severity Score Index (MSSI) as a measure of disease severity to study the effects of ERT in a population of 30 patients treated with agalsidase alfa for a median of 2.9 years (range, 1.0-6.2 years). Our data show that the MSSI captures the correlation between disease severity and both gender and age (1 - males performing worse than females at baseline and 2 - severity of diseases progresses with age in both sex). Furthermore, after at least 1 year of ERT, total MSSI scores were significantly lower than those at baseline (p < 0.001), suggesting a marked clinical improvement under ERT. In conclusion, the MSSI is a sensitive and useful tool for monitoring disease progression and assessing the effects of ERT in a population of patients from different treatment centres.
authors.affiliation: Rare Metabolic Diseases Unit Fondazione Mariani, Pediatric Clinic, Azienda Ospedaliera San Gerardo, Monza, Italy. rossella.parini@pediatriamonza.it
authors.forename: R
authors.initials: R
authors.lastname: Parini
authors.forename: M
authors.initials: M
authors.lastname: Rigoldi
authors.forename: F
authors.initials: F
authors.lastname: Santus
authors.forename: F
authors.initials: F
authors.lastname: Furlan
authors.forename: P
authors.initials: P
authors.lastname: De Lorenzo
authors.forename: G
authors.initials: G
authors.lastname: Valsecchi
authors.forename: D
authors.initials: D
authors.lastname: Concolino
authors.forename: P
authors.initials: P
authors.lastname: Strisciuglio
authors.forename: S
authors.initials: S
authors.lastname: Feriozzi
authors.forename: R
authors.initials: R
authors.lastname: Di Vito
authors.forename: R
authors.initials: R
authors.lastname: Ravaglia
authors.forename: R
authors.initials: R
authors.lastname: Ricci
authors.forename: A
authors.initials: A
authors.lastname: Morrone
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D019468:Disease Management; D000795:Fabry Disease / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D007527:Isoenzymes / Q000627:therapeutic use; D007558:Italy; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012720:Severity of Illness Index; D012737:Sex Factors; D016896:Treatment Outcome; D000519:alpha-Galactosidase / Q000627:therapeutic use*
chemical_list: D007527:Isoenzymes; D011994:Recombinant Proteins; C000627036:agalsidase alfa; D000519:alpha-Galactosidase